Insmed Statistics
Total Valuation
Insmed has a market cap or net worth of $25.71 billion. The enterprise value is $25.29 billion.
| Market Cap | 25.71B |
| Enterprise Value | 25.29B |
Important Dates
The last earnings date was Thursday, October 29, 2026, before market open.
| Earnings Date | Oct 29, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Insmed has 219.38 million shares outstanding. The number of shares has increased by 13.67% in one year.
| Current Share Class | 219.38M |
| Shares Outstanding | 219.38M |
| Shares Change (YoY) | +13.67% |
| Shares Change (QoQ) | +0.66% |
| Owned by Insiders (%) | 0.62% |
| Owned by Institutions (%) | 104.64% |
| Float | 217.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.76 |
| Forward PS | 9.29 |
| PB Ratio | 35.06 |
| P/TBV Ratio | 54.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 16.49 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.86, with a Debt / Equity ratio of 1.01.
| Current Ratio | 2.86 |
| Quick Ratio | 2.36 |
| Debt / Equity | 1.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.78 |
Financial Efficiency
Return on equity (ROE) is -72.45% and return on invested capital (ROIC) is -25.18%.
| Return on Equity (ROE) | -72.45% |
| Return on Assets (ROA) | -17.25% |
| Return on Invested Capital (ROIC) | -25.18% |
| Return on Capital Employed (ROCE) | -38.85% |
| Weighted Average Cost of Capital (WACC) | 8.70% |
| Revenue Per Employee | $913,294 |
| Profits Per Employee | -$363,948 |
| Employee Count | 1,664 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 1.66 |
Taxes
In the past 12 months, Insmed has paid $7.55 million in taxes.
| Income Tax | 7.55M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.34% in the last 52 weeks. The beta is 0.81, so Insmed's price volatility has been lower than the market average.
| Beta (5Y) | 0.81 |
| 52-Week Price Change | -37.34% |
| 50-Day Moving Average | 111.11 |
| 200-Day Moving Average | 123.74 |
| Relative Strength Index (RSI) | 64.96 |
| Average Volume (20 Days) | 3,769,613 |
Short Selling Information
The latest short interest is 13.48 million, so 6.14% of the outstanding shares have been sold short.
| Short Interest | 13.48M |
| Short Previous Month | 13.80M |
| Short % of Shares Out | 6.14% |
| Short % of Float | 6.18% |
| Short Ratio (days to cover) | 4.85 |
Income Statement
In the last 12 months, Insmed had revenue of $1.52 billion and -$605.61 million in losses. Loss per share was -$2.80.
| Revenue | 1.52B |
| Gross Profit | 1.28B |
| Operating Income | -633.13M |
| Pretax Income | -598.06M |
| Net Income | -605.61M |
| EBITDA | -611.03M |
| EBIT | -633.13M |
| Loss Per Share | -$2.80 |
Balance Sheet
The company has $1.15 billion in cash and $730.94 million in debt, with a net cash position of $415.69 million or $1.89 per share.
| Cash & Cash Equivalents | 1.15B |
| Total Debt | 730.94M |
| Net Cash | 415.69M |
| Net Cash Per Share | $1.89 |
| Equity (Book Value) | 726.21M |
| Book Value Per Share | 3.31 |
| Working Capital | 1.11B |
Cash Flow
In the last 12 months, operating cash flow was -$595.62 million and capital expenditures -$31.95 million, giving a free cash flow of -$627.58 million.
| Operating Cash Flow | -595.62M |
| Capital Expenditures | -31.95M |
| Depreciation & Amortization | 22.09M |
| Net Borrowing | -3.25M |
| Free Cash Flow | -627.58M |
| FCF Per Share | -$2.86 |
Margins
Gross margin is 84.40%, with operating and profit margins of -41.66% and -39.85%.
| Gross Margin | 84.40% |
| Operating Margin | -41.66% |
| Pretax Margin | -39.35% |
| Profit Margin | -39.85% |
| EBITDA Margin | -40.21% |
| EBIT Margin | -41.66% |
| FCF Margin | n/a |
Dividends & Yields
Insmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -13.67% |
| Shareholder Yield | -13.67% |
| Earnings Yield | -2.39% |
| FCF Yield | -2.46% |
Analyst Forecast
The average price target for Insmed is $194.18, which is 65.70% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $194.18 |
| Price Target Difference | 65.70% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 24 |
| Revenue Growth Forecast (3Y) | 87.07% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on March 3, 2011. It was a reverse split with a ratio of 1:10.
| Last Split Date | Mar 3, 2011 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Insmed has an Altman Z-Score of 8.99 and a Piotroski F-Score of 4.
| Altman Z-Score | 8.99 |
| Piotroski F-Score | 4 |